CDSCO approves AstraZeneca’s Dapagliflozin with additional indication for treating CKD and heart failure patients Read more
Dapagliflozin reduces cardiovascular death risk in patients with preserved ejection fraction Read more
Japan approves Forxiga to treat chronic kidney disease in patients with and without type-II diabetes Read more
SGLT-2 inhibitors may primarily drive growth of branded heart failure treatment market: GlobalData Read more